Agenus' Brain Cancer Vaccine Results to be Presented at Plenary Session of the
81st American Association of Neurological Surgeons (AANS) Annual Scientific
First Phase 2 Data From Prophage G-100 (HSPPC-96) Newly Diagnosed Glioma
LEXINGTON, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN)
reported today that Orin Bloch, MD, Clinical Instructor, Department of
Neurological Surgery, University of California San Francisco (UCSF), will
present an abstract that reports on outcomes with HSPPC-96 vaccination in
patients with newly diagnosed glioma at the 81^st American Association of
Neurological Surgeons (AANS) Annual Scientific Meeting in New Orleans,
Louisiana, April 27-May 1, 2013. Dr. Bloch's presentation will be given during
Plenary Session III of the AANS meeting on May 1, 2013 at 10:19 am ET.
Dr. Bloch is a lead medical scientist working on the study at UCSF. Dr. Parsa,
MD, Ph.D., who is currently at UCSF and will soon join Northwestern University
as the newly appointed Chair of the Department of Neurological Surgery, is the
lead clinical investigator for Prophage Series G-100 and G-200 in newly
diagnosed and recurrent glioblastoma, respectively.
HSP Platform: The Prophage Series Cancer Vaccines
The Prophage Series of vaccines are patient-specific therapeutic cancer
vaccine candidates. They contain heat shock protein gp96 and associated
peptides that are purified from patient tumor tissue.Prophage Series vaccines
are designed to target only cancerous cells, not healthy normal cells, and
limit the toxicities associated with traditional broad-acting cancer
Prophage Series G-100 and G-200 are being studied in two different settings of
glioma: newly diagnosed and recurrent disease.Glioma is the deadliest form of
brain cancer with an average survival of six to 14 months.
Promising results from an earlier Phase 2 trial in patients with recurrent
glioma treated with Prophage Series G-200 were presented at the 2012 AANS
Annual Meeting. In the 2012 AANS presentation, over 40 patients were treated
and the population evaluated for efficacy had a median Karnofsky performance
status (KPS) of 80 and median age of 53. Patients treated with G-200 lived
significantly longer than 86 consecutive patients not enrolled in the G-200
clinical trial, but treated with alternative therapies during the study
The control patients had equivalent criteria; >90 percent resection of
recurrent GBM and had a KPS>70.The median overall survival for these patients
was only 32.8 weeks with a six-month survival of 68 percent compared to a
median survival of 47.6 weeks and 93 percent 6 month survival rate for the
vaccine treated group (p<0.01). The vaccine was well tolerated, with no
related grade 3 or grade 4 toxicities.
The available survival data indicate that the G-200 vaccine may help patients
live longer, which would suggest a clinical benefit. In addition, the
researchers noted that G-200 results are superior to similar surgical
populations identified in the literature.
This trial is sponsored by Dr. Andrew Parsa and primarily supported through
funding from the American Brain Tumor Association, Accelerated Brain Cancer
Cure, National Brain Tumor Society, and National Cancer Institute Special
Programs of Research Excellence. Drs. Parsa and Bloch have not received any
financial support or travel expense reimbursement for this work or for
consulting activities on behalf of Agenus.Drs. Parsa and Bloch do not have an
equity interest in Agenus or a financial relationship with the company.
Agenus Inc. is a biotechnology company working to develop treatments for
cancers and infectious diseases. The company is focused on immunotherapeutic
products based on strong platform technologies with multiple product
candidates advancing through the clinic, including several product candidates
that have advanced into late-stage clinical trials through corporate partners.
Between Agenus and its partners, 19 programs are in clinical development. For
more information, please visit www.agenusbio.com.
The Agenus logo is available at
This press release contains forward-looking statements, including statements
regarding clinical trial activities and the presentation of data. These
forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors section of
our Annual Report on Form 10-K filed with the Securities and Exchange
Commission for the period ended December 31, 2012. Agenus cautions investors
not to place considerable reliance on the forward-looking statements contained
in this release. These statements speak only as of the date of this document,
and Agenus undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their entirety by this
cautionary statement. Agenus' business is subject to substantial risks and
uncertainties, including those identified above. When evaluating Agenus'
business and securities, investors should give careful consideration to these
risks and uncertainties.
CONTACT: Media and Investor Contact:
Jonae R. Barnes
Investor Relations and
Press spacebar to pause and continue. Press esc to stop.